Introduction | Outcome nomenclature | EffTox | Wages & Tait | BOIN12 | Implementation in escalation | Final dose selection | RDS tabulation | Dose paths | Simulation | References

Introduction | Summary of the BOIN Design | Implementation in escalation | Final dose selection | Dose paths | Simulation | References

Introduction | Outcome nomenclature | BOIN-COMB | Implementation in escalation | Final dose selection | Combination with other dose selectors | Dose paths | Simulation | References

Introduction | Summary of the CRM Design | Hyperbolic tangent model | Empiric model (aka power model) | One-parameter logistic model | Two-parameter logistic model | Priors | Toxicity skeletons and standardised doses | Implementation in escalation | dfcrm | trialr | dfcrm vs trialr | Dose paths | Simulation | References

Introduction | Summary of the mTPI Design | Implementation in escalation | Final dose selection | Dose paths | Simulation | References

Summary of the design | Implementation in escalation | Future work | Dose paths | Simulation | References

Introduction | TITE-CRM | TITE-NBG | Implementation in escalation | Dose paths | Simulation | References

Introduction | Summary of the TPI Design | Implementation in escalation | Final dose selection | Dose paths | Simulation | References

Introduction | Supported Interface

Introduction | Comparing competing designs | Working with PatientSamples | Exporting the underlying latent variables | Calculating potential outcomes | Importing the underlying latent variables | Correlated toxicity and efficacy outcomes | Further refinements | References

Introduction | Simulating trials in escalation | The simplest example | A more complex example | Further refinements | Cohort size | Sampling the conclusion of partly-observed trials | Next dose | All model fits | Big trials | References

Introduction | Other Models | CRM | BOIN | Further options | Non-uniform cohorts | Partially completed trials | Next dose | Crystallised dose-paths | Dose-paths vs simulation | References